E-28 | International Percutaneous Coronary Intervention Complication Survey
Notice bibliographique
Résumé
BackgroundThe perceptions and management strategies of interventional cardiologists (ICs) of percutaneous coronary intervention (PCI) complications have received limited study.MethodsOnline survey on PCI complications: 46 questions were distributed via email lists and Twitter to ICs.ResultsOf 821 participants, 60% were from the United States with a median age group of 46-50 years. Annual PCI case numbers were <100 (26%), 100-199 (37%), 200-299 (21%), and ≥300 (16%); 42% do not perform structural interventions, others reported performing <40 (30%), >100 (11%) structural cases annually. On a scale of 0-10, participating ICs were highly concerned about potential complications with a median score of 6.7 (IQR: 5.1-8.7). The types of complications reported by ICs during the past year are shown in the Figure. The most feared complication was death (39%), followed by coronary perforation (26%) and stroke (9%). Covered stents were never deployed by 21%, and 32% deployed at least one during the past year; 79% have never used fat to seal perforations, and 5% used it during the past year; 64% have never used coils for perforations, and 10% used them during the past year. Complications were attributed to higher patient/angiographic complexity by 69% and seen as opportunities for improvement by 69%; 97% of participants were interested in learning more about the management of PCI complications. The most useful learning Methods were meetings (66%), webinars (48%), YouTube (32%), and Twitter (29%).ConclusionsDisclosuresL. Azzalini: Honoraria from Abbott Vascular, Guerbet, Terumo, and Sahajanand Medical Technologies and research support from ACIST Medical Systems, Guerbet, and Terumo.: Consulting; A. B. Hall: A. Hall reports speaker fees/honoraria from Medtronic, OpSens Medical and Cardiovascular Innovations Foundation.: Consulting; K. J. Croce: Abbott: Advisory Board/Board Member and Consulting; Abiomed: Advisory Board/Board Member and Consulting; Boston Scientific Corp.: Advisory Board/Board Member and Consulting; Cardiovascular Systems, Inc.: Advisory Board/Board Member and Consulting; Philips: Advisory Board/Board Member and Consulting; dyad: Ownership Interests: Stocks, Stock Options; takeda: Consulting; biotronik: Consulting; S. Banerjee: Medtronic: Consulting; Cordis: Consulting; Kaneka: Consulting; Boston Scientific Corp.: Principal Investigator for a Research Study; Chiesi: Principal Investigator for a Research Study; M. H. Shishehbor: Abbott: Advisory Board/Board Member and Consulting; Boston Scientific Corp.: Advisory Board/Board Member and Consulting; Medtronic: Advisory Board/Board Member and Consulting; Philips: Advisory Board/Board Member and Consulting; P. Sorajja: Abbott: Advisory Board/Board Member and Consulting; W. L. Lombardi: Boston Scientific Corp.: Advisory Board/Board Member and Consulting; Abiomed: Consulting; Medtronic: Consulting; wife employee: Employed or Salary; Rampart IC: Ownership Interests: Stocks, Stock Options; Asahi intecc: Consulting and Royalties; E. S. Brilakis: Abbott: Consulting and Speaker Bureau; AMgen: Consulting and Speaker Bureau; Asahi Intecc: Speaker Bureau; Biotronik: Consulting and Speaker Bureau; Boston Scientific Corp.: Consulting, Principal Investigator for a Research Study and Speaker Bureau; ControlRad: Speaker Bureau; CSI: Consulting and Speaker Bureau; GE Healthcare: Consulting, Principal Investigator for a Research Study and Speaker Bureau; Hippocrates LLC: Ownership Interests: Stocks, Stock Options; MHI Ventures: Ownership Interests: Stocks, Stock Options; Cleerly Health: Ownership Interests: Stocks, Stock Options; Stallion Medical: Ownership Interests: Stocks, Stock Options; B. Simsek Nothing to disclose. S. Kostantinis Nothing to disclose. J. Karacsonyi Nothing to disclose. Y. B. Sandoval Nothing to disclose. M. McEntegart Nothing to disclose. O. C. Mastrodemos Nothing to disclose. B. V. Rangan Nothing to disclose. BackgroundThe perceptions and management strategies of interventional cardiologists (ICs) of percutaneous coronary intervention (PCI) complications have received limited study. The perceptions and management strategies of interventional cardiologists (ICs) of percutaneous coronary intervention (PCI) complications have received limited study. MethodsOnline survey on PCI complications: 46 questions were distributed via email lists and Twitter to ICs. Online survey on PCI complications: 46 questions were distributed via email lists and Twitter to ICs. ResultsOf 821 participants, 60% were from the United States with a median age group of 46-50 years. Annual PCI case numbers were <100 (26%), 100-199 (37%), 200-299 (21%), and ≥300 (16%); 42% do not perform structural interventions, others reported performing <40 (30%), >100 (11%) structural cases annually. On a scale of 0-10, participating ICs were highly concerned about potential complications with a median score of 6.7 (IQR: 5.1-8.7). The types of complications reported by ICs during the past year are shown in the Figure. The most feared complication was death (39%), followed by coronary perforation (26%) and stroke (9%). Covered stents were never deployed by 21%, and 32% deployed at least one during the past year; 79% have never used fat to seal perforations, and 5% used it during the past year; 64% have never used coils for perforations, and 10% used them during the past year. Complications were attributed to higher patient/angiographic complexity by 69% and seen as opportunities for improvement by 69%; 97% of participants were interested in learning more about the management of PCI complications. The most useful learning Methods were meetings (66%), webinars (48%), YouTube (32%), and Twitter (29%). Of 821 participants, 60% were from the United States with a median age group of 46-50 years. Annual PCI case numbers were <100 (26%), 100-199 (37%), 200-299 (21%), and ≥300 (16%); 42% do not perform structural interventions, others reported performing <40 (30%), >100 (11%) structural cases annually. On a scale of 0-10, participating ICs were highly concerned about potential complications with a median score of 6.7 (IQR: 5.1-8.7). The types of complications reported by ICs during the past year are shown in the Figure. The most feared complication was death (39%), followed by coronary perforation (26%) and stroke (9%). Covered stents were never deployed by 21%, and 32% deployed at least one during the past year; 79% have never used fat to seal perforations, and 5% used it during the past year; 64% have never used coils for perforations, and 10% used them during the past year. Complications were attributed to higher patient/angiographic complexity by 69% and seen as opportunities for improvement by 69%; 97% of participants were interested in learning more about the management of PCI complications. The most useful learning Methods were meetings (66%), webinars (48%), YouTube (32%), and Twitter (29%). Conclusions DisclosuresL. Azzalini: Honoraria from Abbott Vascular, Guerbet, Terumo, and Sahajanand Medical Technologies and research support from ACIST Medical Systems, Guerbet, and Terumo.: Consulting; A. B. Hall: A. Hall reports speaker fees/honoraria from Medtronic, OpSens Medical and Cardiovascular Innovations Foundation.: Consulting; K. J. Croce: Abbott: Advisory Board/Board Member and Consulting; Abiomed: Advisory Board/Board Member and Consulting; Boston Scientific Corp.: Advisory Board/Board Member and Consulting; Cardiovascular Systems, Inc.: Advisory Board/Board Member and Consulting; Philips: Advisory Board/Board Member and Consulting; dyad: Ownership Interests: Stocks, Stock Options; takeda: Consulting; biotronik: Consulting; S. Banerjee: Medtronic: Consulting; Cordis: Consulting; Kaneka: Consulting; Boston Scientific Corp.: Principal Investigator for a Research Study; Chiesi: Principal Investigator for a Research Study; M. H. Shishehbor: Abbott: Advisory Board/Board Member and Consulting; Boston Scientific Corp.: Advisory Board/Board Member and Consulting; Medtronic: Advisory Board/Board Member and Consulting; Philips: Advisory Board/Board Member and Consulting; P. Sorajja: Abbott: Advisory Board/Board Member and Consulting; W. L. Lombardi: Boston Scientific Corp.: Advisory Board/Board Member and Consulting; Abiomed: Consulting; Medtronic: Consulting; wife employee: Employed or Salary; Rampart IC: Ownership Interests: Stocks, Stock Options; Asahi intecc: Consulting and Royalties; E. S. Brilakis: Abbott: Consulting and Speaker Bureau; AMgen: Consulting and Speaker Bureau; Asahi Intecc: Speaker Bureau; Biotronik: Consulting and Speaker Bureau; Boston Scientific Corp.: Consulting, Principal Investigator for a Research Study and Speaker Bureau; ControlRad: Speaker Bureau; CSI: Consulting and Speaker Bureau; GE Healthcare: Consulting, Principal Investigator for a Research Study and Speaker Bureau; Hippocrates LLC: Ownership Interests: Stocks, Stock Options; MHI Ventures: Ownership Interests: Stocks, Stock Options; Cleerly Health: Ownership Interests: Stocks, Stock Options; Stallion Medical: Ownership Interests: Stocks, Stock Options; B. Simsek Nothing to disclose. S. Kostantinis Nothing to disclose. J. Karacsonyi Nothing to disclose. Y. B. Sandoval Nothing to disclose. M. McEntegart Nothing to disclose. O. C. Mastrodemos Nothing to disclose. B. V. Rangan Nothing to disclose. L. Azzalini: Honoraria from Abbott Vascular, Guerbet, Terumo, and Sahajanand Medical Technologies and research support from ACIST Medical Systems, Guerbet, and Terumo.: Consulting; A. B. Hall: A. Hall reports speaker fees/honoraria from Medtronic, OpSens Medical and Cardiovascular Innovations Foundation.: Consulting; K. J. Croce: Abbott: Advisory Board/Board Member and Consulting; Abiomed: Advisory Board/Board Member and Consulting; Boston Scientific Corp.: Advisory Board/Board Member and Consulting; Cardiovascular Systems, Inc.: Advisory Board/Board Member and Consulting; Philips: Advisory Board/Board Member and Consulting; dyad: Ownership Interests: Stocks, Stock Options; takeda: Consulting; biotronik: Consulting; S. Banerjee: Medtronic: Consulting; Cordis: Consulting; Kaneka: Consulting; Boston Scientific Corp.: Principal Investigator for a Research Study; Chiesi: Principal Investigator for a Research Study; M. H. Shishehbor: Abbott: Advisory Board/Board Member and Consulting; Boston Scientific Corp.: Advisory Board/Board Member and Consulting; Medtronic: Advisory Board/Board Member and Consulting; Philips: Advisory Board/Board Member and Consulting; P. Sorajja: Abbott: Advisory Board/Board Member and Consulting; W. L. Lombardi: Boston Scientific Corp.: Advisory Board/Board Member and Consulting; Abiomed: Consulting; Medtronic: Consulting; wife employee: Employed or Salary; Rampart IC: Ownership Interests: Stocks, Stock Options; Asahi intecc: Consulting and Royalties; E. S. Brilakis: Abbott: Consulting and Speaker Bureau; AMgen: Consulting and Speaker Bureau; Asahi Intecc: Speaker Bureau; Biotronik: Consulting and Speaker Bureau; Boston Scientific Corp.: Consulting, Principal Investigator for a Research Study and Speaker Bureau; ControlRad: Speaker Bureau; CSI: Consulting and Speaker Bureau; GE Healthcare: Consulting, Principal Investigator for a Research Study and Speaker Bureau; Hippocrates LLC: Ownership Interests: Stocks, Stock Options; MHI Ventures: Ownership Interests: Stocks, Stock Options; Cleerly Health: Ownership Interests: Stocks, Stock Options; Stallion Medical: Ownership Interests: Stocks, Stock Options; B. Simsek Nothing to disclose. S. Kostantinis Nothing to disclose. J. Karacsonyi Nothing to disclose. Y. B. Sandoval Nothing to disclose. M. McEntegart Nothing to disclose. O. C. Mastrodemos Nothing to disclose. B. V. Rangan Nothing to disclose.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,003 | 0,009 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,002 | 0,002 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,001 | 0,001 |
| Science ouverte | 0,001 | 0,002 |
| Intégrité de la recherche | 0,001 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,021 | 0,007 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».